External Advisory Committee

The Delaware INBRE External Advisory Committee (EAB), comprised of senior representatives from academia, the biomedical industry, the medical community, and government labs provides strategic comment and guidance to the PI and the Steering Committee on scientific, administrative, and other matters relevant to the INBRE program. 

The EAB meets annually in Delaware to review program progress and recommend mid-course modifications where necessary.  The External Advisory Board, acting as an external review board, and in partnership with the Steering Committee and the Research Committee, also helped select the Phase 2 research proposal funded starting in Year 3.  The seven-member INBRE Board includes three members of the original BRIN board who guided Delaware through the establishment of the BRIN Network.  The INBRE Board was expanded in size and expertise to meet the increased scope of the INBRE program.

The Members of the Delaware INBRE External Advisory Committee are:

• Dr. Mark Lively – Chair; Professor of Biochemistry, Wake Forest University School of Medicine
• Dr. Lynda Bonewald; Lefkowitz Professor of Oral Biology and Director of the Bone Biology Research Program, School of Dentistry, University of Missouri at Kansas City
• Dr. Georgia Dunston; Founding Director, National Human Genome Center; Co-Director Molecular Genetics, NHGC and Chair, Department of Microbiology, Howard University
• Dr. David Landsman; Chief, Computational Biology Branch, National Institutes of Health
• Dr. Michael Liebman; Senior Institute Fellow, Windber Research Institute and President, Strategic Medicine, Inc.
• Dr. David Speicher; Professor, Molecular and Cellular Oncogenesis Program, The Wistar Institute
• Dr. Richard Quisenberry; Executive Director, The AMTEX Partnership

[View Proposals]